InvestorsHub Logo
Followers 34
Posts 2992
Boards Moderated 0
Alias Born 02/27/2016

Re: None

Tuesday, 04/09/2019 8:03:18 AM

Tuesday, April 09, 2019 8:03:18 AM

Post# of 458784
Value-Creating Catalysts – Clinical updates from Phase 2 Parkinson’s disease dementia study, Phase 2b/3 Alzheimer’s disease and Phase 2 Rett syndrome studies anticipated in 2019. Clinical data publications and additional indications to be announced in 2019.

So many to choose from. What could it be?

Anxiety disorders, mood disorders, psychotic disorders, etc.

Come on Merck, let's do this partnership for these other indications.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News